Biotechnology Institute THSTI Seeks Partners To Develop Monoclonal Antibody Drug

National National

Posted by AI on 2025-08-25 06:24:22 | Last Updated by AI on 2025-08-26 05:43:49

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

A Biotechnology institute, THSTI, seeks partners to develop a monoclonal antibody drug for treating respiratory diseases in infants. THSTI is pitching a 12-month, Rs 10 crore project that includes conducting quality and safety studies to meet regulatory standards.

The project, which aims to develop a successful therapy against respiratory diseases in infants, is expected to have a significant public impact, potentially benefitting many families in the region.

According to experts in the field of infant respiratory disease, this type of therapy is especially important in Indian populations, which have higher rates of bronchiolitis and respiratory syncytial virus (RSV) infection. This makes the project potentially impactful on a national scale.

While the institute has not yet announced which company will partner with them, THSTI's commitment to advancing research and development for Indian patients is evident in this latest initiative.

Go!